bleomycin + cisplatin + etoposide + ifosfamide

This is a four-drug chemotherapy combination regimen consisting of bleomycin, cisplatin, etoposide, and ifosfamide. Each component has a distinct mechanism of action targeting rapidly dividing cancer cells:

• Bleomycin is an antitumor antibiotic that induces DNA strand breaks through free radical formation.
• Cisplatin is a platinum-based compound that forms DNA crosslinks, inhibiting DNA synthesis and function.
• Etoposide inhibits topoisomerase II, leading to double-strand DNA breaks during replication.
• Ifosfamide is an alkylating agent that causes crosslinking of DNA strands.

This combination may be used in the treatment of various germ cell tumors (including testicular cancer), particularly in patients with poor prognosis or those who cannot tolerate standard regimens such as BEP (bleomycin/etoposide/cisplatin) or VIP (etoposide/ifosfamide/cisplatin). The addition of ifosfamide to the BEP backbone can be considered for high-risk or relapsed cases. The regimen requires careful monitoring due to cumulative toxicities including pulmonary toxicity (bleomycin), nephrotoxicity and ototoxicity (cisplatin), myelosuppression (etoposide and ifosfamide), neurotoxicity, hemorrhagic cystitis (ifosfamide), and risk for secondary malignancies.